Amendments to the Specification

Please replace the present title as follows:

~~HYBRID PROTEINS~~ HYBRID HETERODIMERIC PROTEIN HORMONE AND METHOD OF USING SAME

Please replace the paragraph beginning on page 1, line 3, with the following amended paragraph:

This application is a division of application 09/756,186, filed January 9, 2001 which is a division of application 08/804,166, filed February 20, 1997, which claims the benefit of U.S. Provisional Application no. 60/011,936, filed February 20, 1996, the entire contents of each of the above applications being incorporated herein by reference.

Please replace the paragraph beginning on page 13, line 4, with the following amended paragraph:

Cell lines used in this study were obtained from the American Type Culture Collection (ATCC), ~~Rockville, Maryland~~ 10801 University Boulevard, Manassas, Virginia 20110-2209, unless otherwise specified. The CHO-DUKX cell line was obtained from L. Chasin at Columbia University through D. Houseman at MIT (39). The CHO-DUKX cells, which lack a functional gene for dihydrodolate reductase, were routinely maintained in complete α-plus Modified Eagles Medium (α(+)MEM) supplemented with 10% fetal

bovine serum (FBS). The COS-7 cells were routinely maintained in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% FBS. Unless specified otherwise, cells were split to maintain them in log phase of growth, and culture reagents were obtained from GIBCO (Grand Island, New York).

On page 23, after line 17, please insert Tables 1 and 2 as follows:

Table 1: COS-7 transient expression (TBP ELISA)

Hybrid Protein	Concentration (pg/ml)
TBP1	66
TBP-hCGα(20-161)	5.1
TBP-hCGβ(20-161)	0.5
TBP-hCG(20-161)	2.7
Control	<0.25

Constructs were expressed using pSVL (Pharmacia)

Table 2: COS-7 transient expression (TBP ELISA)

Hybrid Protein	Concentration (ng/ml)
TBP1	131
TBP-hCGα(20-190)	81
TBP-hCGβ(20-190)	9
TBP-hCG(20-190)	62
Control	<1

Constructs were expressed using a mouse Metallothionein promoter-containing vector = pDα

On page 23, after line 23, please insert Table 3 as follows:

Table 3: COS-7 transient expression (hCG heterodimer assay)	
Hybrid Protein	Concentration (ng/ml)
TBP1	<0.2
TBP-hCGα(20-190)	<0.2
TBP-hCGβ(20-190)	<0.2
TBP-hCG(20-190)	38
Control	<0.2

Constructs were expressed using a mouse metallothionein promoter-containing vector – pDα

On page 23, after line 29, please insert Table 4 as follows:

Table 4: Samples tested for anti-TNF activity		
Construct	Cell source	Nature of sample
r-hTBP-1	CHO	Purified
TBP-lgG3	CHO	1x conditioned media
TBP(20-161)hCG	CHO	Immunopurified (anti-TBP)
TBP(20-190)-hCG	CHO	1x conditioned media
TBP(20-190)-hCG	COS	1x conditioned media

On page 24, after line 18, please insert Table 5 as follows:

Table 5: Preliminary Assessment of the hybrid proteins in TNF Cytotoxicity Assay		
Construct	Fusion partner	Anti-TNF activity (ED50) in BT-20 bioassay**
r-hTBP-1	None	100 ng/ml
TBP-lgG3	IgG3 heavy chain constant region	1.5 ng/ml
TBP(20-161)-hCG	HCGα and hCGβ (heterodimer)	2 ng/ml
TBP(20-190)-hCG	HCGα and hCGβ (heterodimer)	8-11 ng/ml

** The quantitation of material for dosing and estimation of ED50 was made using the TBP ELISA.

Page 26, please delete Tables 1 and 2.

Page 27, please delete Tables 3 and 4.

Page 28, please delete Table 5.

Please delete the attached Sequence Listing section pages 32-45.